CLAIMS

1. Use of an antibody comprising a heavy chain variable region comprising SEQ ID NO:2 and a light chain variable region comprising SEQ ID NO:3, for the manufacture of a pharmaceutical composition for obtaining inhibition of the progression of structural damage in a subject suffering from Rheumatoid Arthritis, wherein said medicament is to be administered with an effective amount of methotrexate, and wherein the antibody is to be administered subcutaneously to the subject between 150 and 200 mg per two weeks.

2. Use of an antibody comprising a heavy chain variable region comprising SEQ ID NO:2 and a light chain variable region comprising SEQ ID NO:3 in a combination with methotrexate for the preparation of a medicament for obtaining inhibition of the progression of structural damage in a subject suffering from Rheumatoid Arthritis wherein the medicament is formulated to be subcutaneously administer said antibody to a subject at between 150 and 200 mg per two weeks.

3 The use according to claim 1 or 2, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.6.

4. The use of any one of claims 1 to 3, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 1.

5. The use of any one of claims 1 to 4, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administering methotrexate.

6. The use of any one of claims 1 to 5, wherein methotrexate is to be administered between 6 to 25 mg per week.

7. The use of any one of claims 1 to 6, wherein the antibody is sarilumab.

8. The use of any of claim 1 to 7, wherein the antibody is to be administered at 150 mg per two weeks.

9. The use of any of claim 1 to 7, wherein the antibody is to be administered at 200 mg per two weeks.

10. The use of any of claims 1 to 9, wherein the antibody is to be administered to the subject for at least 52 weeks.

11. The use of any one of claims 1 to 10, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.2.

12. The use of any one of claims 1 to 11, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.13.

13. The use of any one of claims 1 to 12, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.3.

14. The use of any one of claims 1 to 13, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.25.